[1] Abbott A. Dementia: a problem for our age. Nature, 2011, 475(7355): S2-4.  doi: 10.1038/475S2a
[2] Miller G. Alzheimer's biomarker initiative hits its stride. Science, 2009, 326(5951): 386-389.  doi: 10.1126/science.326_386
[3] Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med, 2011, 41(4): 283-299.  doi: 10.1053/j.semnuclmed.2011.02.005
[4] Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology, 2003, 226(2): 315-336.
[5] Karas GB, Burton EJ, Rombouts SA, et al. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage, 2003, 18(4): 895-907.  doi: 10.1016/S1053-8119(03)00041-7
[6] Karas GB, Scheltens P, Rombouts SA, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage, 2004, 23(2): 708-716.  doi: 10.1016/j.neuroimage.2004.07.006
[7] Karas G, Sluimer J, Goekoop R, et al. Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol, 2008, 29(5): 944-949.  doi: 10.3174/ajnr.A0949
[8] Chételat G, Landeau B, Eustache F, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage, 2005, 27(4): 934-946.  doi: 10.1016/j.neuroimage.2005.05.015
[9] Shi F, Liu, B, Zhou Y, et al. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies. Hippocampus, 2009, 19(11): 1055-1064.  doi: 10.1002/hipo.20573
[10] 赵彬, 商秀丽, 何志义, 等.阿尔茨海默病的静息态功能磁共振成像低频振幅研究.中国医科大学学报, 2012, (4): 329-332.  doi: 10.3969/j.issn.0258-4646.2012.04.012
[11] Allen G, Barnard H, McColl R, et al. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol, 2007, 64(10): 1482-1487.  doi: 10.1001/archneur.64.10.1482
[12] Wang L, Zang Y, He Y, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage, 2006, 31(2): 496-504.  doi: 10.1016/j.neuroimage.2005.12.033
[13] Remy F, Mirrashed F, Campbell B, et al. Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study. Neuroimage, 2005, 25(1): 253-266.  doi: 10.1016/j.neuroimage.2004.10.045
[14] Han X, M HD, McKeel DJ, et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem, 2002, 82(4): 809-818.  doi: 10.1046/j.1471-4159.2002.00997.x
[15] Rose SE, Chen F, Chalk JB, et al. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry, 2000, 69(4): 528-530.
[16] Yoshiura T, Mihara F, Ogomori K, et al. Diffusion tensor in posterior cingulate gyrus: correlation with cognitive decline in Alzhei-mer's disease. Neuroreport, 2002, 13(17): 2299-2302.  doi: 10.1097/00001756-200212030-00026
[17] Choi SJ, Lim KO, Monteiro I, et al. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study. J Geriatr Psychiatry Neurol, 2005, 18(1): 12-19.  doi: 10.1177/0891988704271763
[18] Nakata Y, Sato N, Abe O, et al. Diffusion abnormality in posterior cingulate fiber tracts in Alzheimer's disease: tract-specific analysis. Radiat Med, 2008, 26(8): 466-473.  doi: 10.1007/s11604-008-0258-3
[19] Ringman JM, O'Neill J, Geschwind D, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain, 2007, 130(Pt 7): 1767-1776.
[20] Medina D, DeToledo-Morrell L, Urresta F, et al. White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging, 2006, 27(5): 663-672.  doi: 10.1016/j.neurobiolaging.2005.03.026
[21] Jessen F, Gur O, Block W, et al. A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI. Neurology, 2009, 72(20): 1735-1740.  doi: 10.1212/WNL.0b013e3181a60a20
[22] Wang Z, Zhao C, Yu L, et al, Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiol, 2009, 50(3): 312-319.  doi: 10.1080/02841850802709219
[23] Bormans GM, Van Oosterwyck G, De Groot TJ, et al. Synthesis and biologic evaluation of (11) c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters. J Nucl Med, 2003, 44(7): 1075-1081.
[24] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol, 2004, 55(3): 306-319.  doi: 10.1002/ana.20009
[25] Shin J, Lee SY, Kim SJ. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage, 2010, 52(2): 488-496.  doi: 10.1016/j.neuroimage.2010.04.013
[26] Zhang W, Oya S, Kung MP, et al. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem, 2005, 48(19): 5980-5988.  doi: 10.1021/jm050166g
[27] Zhang W, Kung MP, Oya S, et al. 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol, 2007, 34(1): 89-97.
[28] Tolboom N, Yaqub M, vanderFlier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med, 2009, 50(2): 191-197.
[29] 华逢春, 冯晓源, 管一晖.轻度认知功能障碍转化阿尔茨海默病方法学研究进展.上海医学影像, 2011, 20(2): 168-172.
[30] Hong MC, Kim YK, Choi JY. Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. Bioorg Med Chem, 2010, 18(22): 7724-7730.  doi: 10.1016/j.bmc.2010.06.044
[31] Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA, 2011, 305(3): 275-283.  doi: 10.1001/jama.2010.2008
[32] Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain, 2011, 134(Pt 4): 1089-1100.
[33] Shao Y, Cherry SR, Farahani K, et al. Simultaneous PET and MR imaging. Phys Med Biol, 1997, 42(10): 1965-1970.  doi: 10.1088/0031-9155/42/10/010
[34] Catana C, Procissi D, Wu Y, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci USA, 2008, 105(10): 3705-3710.  doi: 10.1073/pnas.0711622105
[35] Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med, 2008, 14(4): 459-465.  doi: 10.1038/nm1700
[36] Pichler BJ, Judenhofer MS, Pfannenberg, C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol, 2008, (185 Pt 1): 109-132.
[37] Mosconi L, Sorbi S, de Leon MJ, et al, Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med, 2006. 47(11): 1778-1786.
[38] Zhang Y, Qiu C, Lindberg O, et al, Acceleration of hippocampal atrophy in a non-demented elderly population: the SNAC-K study. Int Psychogeriatr, 2010, 22(1): 14-25.  doi: 10.1017/S1041610209991396
[39] Frey HJ, Mattila KM, Korolainen MA, et al. Problems associated with biological markers of Alzheimer's disease. Neurochem Res, 2005, 30(12): 1501-1510.  doi: 10.1007/s11064-005-8827-7
[40] Ishii K, Minoshima S. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging, 2005, 32(12): 1463-1465.  doi: 10.1007/s00259-005-1936-3
[41] 田金洲, 时晶, 张学凯, 等. 2011年美国阿尔茨海默病最新诊断标准解读.中国医学前沿杂志: 电子版, 2011, 3(4): 91-100.
[42] Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 2005, 53(4): 695-699.  doi: 10.1111/j.1532-5415.2005.53221.x
[43] Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement, 2009, 5(5): 388-397.  doi: 10.1016/j.jalz.2009.07.038